{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:43:50Z","timestamp":1792629830651,"version":"4.5.0"},"reference-count":13,"publisher":"MyJove Corporation","issue":"151","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/59966","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T20:00:09Z","timestamp":1568664009000},"source":"Crossref","is-referenced-by-count":1,"title":["Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice"],"prefix":"10.3791","author":[{"given":"Kyla A.","family":"Britson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron  D.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn  R.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas  E.","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"ref1","first-page":"1","type":"journal-article","article-title":"Estimation of clinical trial success rates and related parameters","volume":"0","author":"Wong","year":"2018","unstructured":"Wong, C. H., Siah, K. W., Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics. 0, 1\u201314 (2018).","journal-title":"Biostatistics"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","type":"journal-article","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","unstructured":"Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., Rosenthal, J. Clinical development success rates for investigational drugs. Nature Biotechnology. 32, 40\u201351 (2014).","journal-title":"Nature Biotechnology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.39048.407928.BE","type":"journal-article","article-title":"Comparison of treatment effects between animal experiments and clinical trials: systematic review","volume":"334","author":"Perel","year":"2007","unstructured":"Perel, P. et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 334, 1\u20136 (2007).","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/clpt.2008.200","type":"journal-article","article-title":"Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients","volume":"85","author":"Rubio-Viqueira","year":"2009","unstructured":"Rubio-Viqueira, B., Hidalgo, M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clinical Pharmacology Therapeutics. 85, 217\u2013221 (2009).","journal-title":"Clinical Pharmacology Therapeutics"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","type":"journal-article","article-title":"Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia","volume":"371","author":"Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine. 371, 1005\u201315 (2014).","journal-title":"New England Journal of Medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1126\/science.1110175","type":"journal-article","article-title":"GDF11 Controls the Timing of Progenitor Cell Competence in Developing Retina","volume":"308","author":"Kim","year":"2005","unstructured":"Kim, J. et al. GDF11 Controls the Timing of Progenitor Cell Competence in Developing Retina. Science. 308, 1927\u20131930 (2005).","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"21037","DOI":"10.1074\/jbc.M110.114959","type":"journal-article","article-title":"Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIB","volume":"285","author":"Sako","year":"2010","unstructured":"Sako, D. et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIB. Journal of Biological Chemisty. 285, 21037\u201321048 (2010).","journal-title":"Journal of Biological Chemisty"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/hmg\/ddu028","type":"journal-article","article-title":"Human skeletal muscle xenograft as a new preclinical model for muscle disorders","volume":"23","author":"Zhang","year":"2014","unstructured":"Zhang, Y. et al. Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Human Molecular Genetics. 23, 3180\u20133188 (2014).","journal-title":"Human Molecular Genetics"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0092-8674(02)00826-7","type":"journal-article","article-title":"Inappropriate Gene Activation in FSHD : A Repressor Complex Binds a Chromosomal Repeat Deleted in Dystrophic Muscle","volume":"110","author":"Gabellini","year":"2002","unstructured":"Gabellini, D., Green, M. R., Tupler, R. Inappropriate Gene Activation in FSHD : A Repressor Complex Binds a Chromosomal Repeat Deleted in Dystrophic Muscle. Cell. 110, 339\u2013348 (2002).","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","type":"journal-article","article-title":"A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy","volume":"329","author":"Lemmers","year":"2010","unstructured":"Lemmers, R. J. L. F. et al. A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy. Science. 329, 1650\u20131654 (2010).","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","type":"journal-article","article-title":"Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics","volume":"24","author":"Chen","year":"2016","unstructured":"Chen, J. C. J. et al. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. Molecular Therapy. 24, 1405\u20131411 (2016).","journal-title":"Molecular Therapy"},{"key":"ref12","volume-title":"Aids to the investigation of the peripheral nervous system","year":"1943","unstructured":"Medical Research Council. Aids to the investigation of the peripheral nervous system. London: Her Majesty\u2019s Stationary Office (1943).","type":"book"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.celrep.2017.11.008","type":"journal-article","article-title":"Cellular and Molecular Anatomy of the Human Neuromuscular Junction","volume":"21","author":"Jones","year":"2017","unstructured":"Jones, R. A. et al. Cellular and Molecular Anatomy of the Human Neuromuscular Junction. Cell Reports. 21, 2348\u20132356 (2017).","journal-title":"Cell Reports"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/59966\/performing-human-skeletal-muscle-xenografts-in-immunodeficient-mice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:18:49Z","timestamp":1792628329000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/59966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":13,"journal-issue":{"issue":"151","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3791\/59966","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]}}}